Bill Gross warns on gold momentum as regional bank stocks tumble
Investing.com - Piper Sandler has reiterated an Overweight rating on Hinge Health Inc (NYSE:HNGE) with a price target of $70.00, according to a research note released Monday. The stock currently trades at $50.41, representing potential upside to the target following a strong 34% gain over the past six months.
The firm maintains its positive outlook on Hinge Health despite the stock trading down 17% from its post-second quarter 2025 highs, recommending investors buy the dip. InvestingPro data shows the company maintains a strong balance sheet with more cash than debt, while 12 analysts have recently revised their earnings estimates upward.
Piper Sandler identifies Hinge Health as the clear category leader with "deep and defensible competitive moats" in what it describes as an underpenetrated segment of the healthcare benefits market.
The research note specifically highlights newer channel partnerships with major health insurers as providing visibility into consensus estimates for calendar year 2026, potentially suggesting performance above current expectations.
Piper Sandler anticipates Hinge Health’s momentum and track record of positive earnings revisions to continue when the company reports third quarter 2025 results in November.
In other recent news, Hinge Health reported second-quarter results that significantly exceeded market expectations, leading the company to raise its 2025 revenue and EBIT guidance. This strong performance prompted Stifel to increase its price target for Hinge Health to $63, up from $55, while maintaining a Buy rating. Piper Sandler also raised its price target to $70 from $41, following the company’s decision to raise its calendar year 2025 outlook for the second consecutive quarter.
Additionally, Stifel has further adjusted its price target to $66, citing strong growth momentum observed during investor meetings and a proprietary benefit manager survey. Baird initiated coverage on Hinge Health with a Neutral rating and a price target of $56, noting the company’s compelling product offering that addresses critical needs in reducing musculoskeletal-related costs. Piper Sandler reiterated its Overweight rating with a $70 price target, highlighting Hinge Health’s strong technology moats, including its AI-powered 3D motion tracking technology and FDA-cleared wearable device. These developments reflect a positive outlook from analysts and strong business momentum for Hinge Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.